An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
Patients with between 0, 1, 2, or 3 controlled blood counts reported similar scores on the symptom severity survey used in the study.
The prevalence of thrombotic events in patients with myeloproliferative neoplasms can be as high as 39% in some cases.
Researchers probed mutant calreticulins to determine whether they were secreted and behaved extracellularly as cytokines.
Though IFN alfa-2 has been shown to be effective in treating MPNs, it is not the therapy of choice outside of Europe.
Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.
Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.
[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.
Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.
